

PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Postdischarge Follow-up of Infants With Congenital Diaphragmatic Hernia

Section on Surgery and the Committee on Fetus and Newborn

Pediatrics 2008;121:627-632

DOI: 10.1542/peds.2007-3282

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://www.pediatrics.org/cgi/content/full/121/3/627>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2008 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™





CLINICAL REPORT

Postdischarge Follow-up of Infants With Congenital Diaphragmatic Hernia

Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of All Children

Section on Surgery and the Committee on Fetus and Newborn

ABSTRACT

Infants with congenital diaphragmatic hernia often require intensive treatment after birth, have prolonged hospitalizations, and have other congenital anomalies. After discharge from the hospital, they may have long-term sequelae such as respiratory insufficiency, gastroesophageal reflux, poor growth, neurodevelopmental delay, behavior problems, hearing loss, hernia recurrence, and orthopedic deformities. Structured follow-up for these patients facilitates early recognition and treatment of these complications. In this report, follow-up of infants with congenital diaphragmatic hernia is outlined.

INTRODUCTION

Survival rates for patients with congenital diaphragmatic hernia (CDH) have increased during the past decade with the implementation of more “gentle” ventilation and physiology-specific strategies, high-frequency ventilation, extracorporeal membrane oxygenation (ECMO), and improved supportive care.^{1–3} Improvement in survival rates has occurred for infants with CDH complicated by severe pulmonary hypoplasia, pulmonary hypertension, and chronic lung disease.⁴ However, other significant morbidities, such as neurocognitive delay, gastroesophageal reflux, hearing loss, chest wall deformity, poor growth, hernia recurrence, and complications attributable to associated congenital anomalies, continue to affect the lives of many infants with CDH beyond the neonatal period.^{1,5,6}

Coordination of the complex medical and surgical needs of these infants is challenging. Comprehensive multispecialty clinics that aggregate specialty physicians and services are family-friendly and provide for collaborative evaluation and management planning. Same-site multidisciplinary service teams also improve coordination, communication, and support for the medical home pediatrician who is responsible for managing the general health care needs of the infant. Unfortunately, such multispecialty clinics are not available to all infants with CDH. The following information is intended to provide clinicians who care for infants with CDH with a template to organize a comprehensive plan for detection and management of associated morbidities.

PULMONARY MORBIDITY

Survivors with CDH may require treatment beyond the initial hospitalization for chronic lung disease, bronchospasm, pulmonary hypertension, aspiration, pneumonia, and pulmonary hypoplasia. Oxygen treatment beyond the initial hospitalization may be needed for many of these infants, especially those who are treated with ECMO and a prosthetic patch.^{7–9} Many survivors not treated with ECMO also receive bronchodilators and inhaled steroids.⁸ At least 4% of survivors require a long-term tracheostomy.^{9,10} Nearly one fourth of infants with CDH who survive have obstructive airway disease at 5 years of age,^{10,11} and some have pulmonary hypertension that persists for months or years. Pulmonary hypertension that persists for more than the first few weeks after birth is a risk factor for early death.¹² Persistent abnormalities in lung function also have been demonstrated on ventilation/perfusion scans.^{8,12–15}

Pneumonia occurs in approximately 7% of infants with CDH during the first year after birth.^{5,16,17} Aspiration-associated pneumonia and bronchospasm may be reduced in frequency by avoiding oral feeding if oromotor incoordination is significant and by early detection and treatment of gastroesophageal reflux. Pneumonia may be prevented in part by treatment for chronic lung disease, effective management of pulmonary secretions, and immunization with recommended childhood vaccines (such as pneumococcal, influenza, and other recommended vaccines). Palivizumab (respiratory syncytial virus monoclonal antibody; Synagis [MedImmune, Inc, Gaithersburg,

www.pediatrics.org/cgi/doi/10.1542/peds.2007-3282

doi:10.1542/peds.2007-3282

All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

Key Words

congenital diaphragmatic hernia, gastroesophageal reflux, pulmonary hypoplasia, follow-up

Abbreviations

CDH—congenital diaphragmatic hernia
ECMO—extracorporeal membrane oxygenation

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). Copyright © 2008 by the American Academy of Pediatrics

MDJ) also is suggested for infants with CDH who have chronic lung disease, as described in the “Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections” technical report and policy statement by the American Academy of Pediatrics.^{18,19}

Although the incidence of chronic lung disease is 33% to 52% at discharge, most infants who survive CDH have clinical improvement over time.^{6,16,17} Nevertheless, nearly 50% of adult survivors have impairment on pulmonary function testing.¹⁶

GASTROESOPHAGEAL REFLUX/FOREGUT DYSMOTILITY

Gastroesophageal reflux or some form of foregut dysmotility occurs in 45% to 90% of infants with CDH.^{20–24} Abnormal hiatal anatomy at the gastroesophageal junction, lack of an angle of His in some patients, and herniation of the stomach into the chest with distortion are possible mechanisms to explain this high incidence of gastroesophageal reflux. Esophageal dilation or ectasia also has been described in some infants with CDH, and as many as 70% of such infants have severe gastroesophageal reflux.²¹ The incidence of gastroesophageal reflux also correlates with defect size and need for patch repair.^{20,25} Pulmonary morbidity may be worsened by aspiration associated with gastroesophageal reflux. Importantly, a high incidence of esophagitis in adult survivors with CDH suggests that long-term surveillance is needed.²⁶ For all patients with CDH, it is important to have a high index of suspicion for gastroesophageal reflux. Antireflux surgery may be an option for patients with failed medical therapy, although the long-term success rate of this procedure has yet to be proven.

GROWTH FAILURE

Many survivors with CDH fail to grow as well as healthy term infants do and require close nutritional surveillance and intervention.^{6,9,20} Infants with CDH and chronic lung disease often have poor oral feeding skills. Gastroesophageal reflux is common, and oral aversion is frequent; both contribute to growth deficiency. In 1 clinical series, more than 50% of infants with CDH had weight below the 25th percentile.²⁰ Gastrostomy tube placement was performed in 33% of infants in this series. Van Meurs et al⁶ showed that more than 40% of CDH survivors had weight below the 5th percentile at 2 years of age. Gastrostomy tube feeding is suggested by some experts who hypothesize that nasogastric or orogastric tube feeding impairs oral feeding. Others suggest use of nasogastric or orogastric tube feeding for a period of time, especially when success with oral feeding is anticipated within several months. Despite controversy about the most appropriate mode of feeding the infant with CDH at discharge, almost 33% do not orally feed enough fluid volume to support growth and receive feedings through nasogastric or gastrostomy tubes.^{6,20} Early recognition and intervention is essential for optimizing both somatic and alveolar growth and long-term outcomes for infants with CDH.

NEUROCOGNITIVE DELAY AND BEHAVIORAL DISORDERS

Significant developmental delay and behavioral disorders have been reported for a large number of infants with CDH. The infant with a large diaphragmatic defect or need for ECMO is at greatest risk.^{27–36} Nobuhara et al²⁷ reported developmental delay in more than 33% of their CDH survivors. McGahren et al³⁰ described neurologic abnormalities in 67% of infants with CDH who were treated with ECMO compared with 24% of infants with CDH who were not as ill and did not receive ECMO.

The critical illness and physiologic disruption of high-risk infants with CDH places them at risk of neurologic and developmental disabilities. Many infants who present with symptoms of CDH soon after birth are clinically unstable and hypoxemic and require high levels of extraordinary life support such as ECMO and other invasive therapies. Although severity of illness is most predictive of long-term outcome, complications associated with invasive therapies may contribute to morbidity in CDH survivors. In a study by Bernbaum et al³⁷ of survivors receiving ECMO, infants with CDH treated with ECMO had a higher risk of significant neurodevelopmental delays than did infants without CDH. The higher risk of disability in ECMO-treated survivors with CDH compared with ECMO-treated survivors without CDH suggests that at least 3 potential factors may contribute to neurodevelopmental disability in infants with CDH: (1) an intrinsic neurologic abnormality, (2) greater number and severity of morbidities that impair development in infants who require ECMO, (3) and a greater number of ECMO-associated complications.

HEARING LOSS

Sensorineural hearing loss has been described in a number of case series of CDH survivors^{27,28,33,35} and seems to occur in infants regardless of whether they were treated with ECMO. The cause remains unknown, but it is speculated to be related to treatments for respiratory failure (such as hyperventilation, ototoxic medications, or neuromuscular blockade).³⁸ Severe hypoxemia, prolonged ventilation, and ECMO also are risk factors. Approximately half of infants with initially normal hearing assessments develop hearing loss later in infancy.^{39–41}

HERNIA RECURRENCE

Recurrent diaphragmatic hernias have been reported in 8% to 50% of patients with CDH. The single-most important predictor of hernia recurrence is the presence of a large defect that requires a patch to repair.^{2,6,42,43} Recurrences can present from months to years after the initial hospitalization, or the patient can remain asymptomatic. Detection of recurrences may be discovered incidentally on chest radiographs performed for surveillance or other reasons.^{6,43} The lifetime risk of recurrence for a patient with a patch repair is unknown.

ORTHOPEDIC DEFORMITIES

Pectus deformities and progressive asymmetry of the chest wall have been described in CDH survivors.^{27,28,44} The incidence of these orthopedic disorders ranges from

TABLE 1 Recommended Schedule of Follow-up for Infants With CDH

	Before Discharge	1–3 mo After Birth	4–6 mo After Birth	9–12 mo After Birth	15–18 mo After Birth	Annual Through 16 y
Weight, length, occipital-frontal circumference	X	X	X	X	X	X
Chest radiograph	X	If patched	If patched If indicated	If patched	If patched If indicated	If patched If indicated
Pulmonary function testing		X	X	X	X	X
Childhood immunizations	As indicated throughout childhood	X	X	X	X	X
RSV prophylaxis	RSV season during first 2 years after birth (if evidence of chronic lung disease)	X	X	X	X	X
Echocardiogram and cardiology follow-up	X	If previously abnormal or if on supplemental oxygen As indicated	If previously abnormal or if on supplemental oxygen As indicated	If previously abnormal or if on supplemental oxygen As indicated	If previously abnormal or if on supplemental oxygen As indicated	If previously abnormal or if on supplemental oxygen As indicated
Head computed tomography or MRI	If (1) abnormal finding on head ultrasound; (2) seizures/abnormal neurologic findings ^a ; or (3) ECMO or patch repair	X	X	X	X	X
Hearing evaluation ^{4a}	Auditory brainstem evoked response or otoacoustic emissions screen	X	X	X	X	Every 6 mo to age 3 y, then annually to age 5 y
Developmental screening evaluation	X	X	X	X	X	Annually to age 5 y
Neurodevelopmental evaluation	X	X	X	X	X	Annually to age 5 y
Assessment for oral feeding problems	X	X	If oral feeding problems	If oral feeding problems	If oral feeding problems	If oral feeding problems
Upper gastrointestinal study, pH probe, and/or gastric scintiscan	Consider for all patients	If symptoms	If symptoms	Consider for all patients	If symptoms	If symptoms
Esophagoscopy		If symptoms	If symptoms	If symptoms or if abnormal gastrointestinal evaluations	If symptoms	If symptoms
Scoliosis and chest wall deformity screening (physical examination, chest radiograph, and/or computed tomography of the chest)				X		X

The neurosensory tests performed and frequency of surveillance may differ among infants with CDH because of variability in neurologic, developmental, and physiologic impairments. Follow-up should be tailored to each infant. RSV indicates respiratory syncytial virus.

^aMuscle weakness, hypotonia, hypertonia, or other abnormal neurologic sign or symptom.

21% to 48%. Many of them are mild and do not require surgical intervention. Scoliosis also has been found in these patients, with an incidence of 10% to 27%.^{27,44} The incidence of both of these morbidities is higher in patients who have large defects and a patch repair. Periodic and regular follow-up is suggested to detect and prevent development of functionally significant deformities from developing.

OTHER CONGENITAL ABNORMALITIES

Additional congenital anomalies are present in approximately 40% of infants with CDH.⁴⁵⁻⁴⁸ Congenital heart lesions account for nearly two thirds of these anomalies and have a major effect on risk of mortality.^{45,48} Anomalies of the central nervous system, esophageal atresia, and omphalocele also are relatively prevalent compared with other organ systems. A number of syndromes and chromosomal anomalies (such as trisomies 21, 13, and 18; Fryns syndrome; Brachmann-de Lange syndrome; and Pallister-Killian syndrome) include CDH as one of the associated anomalies. Each of these anomalies and syndromes adds to the complexity and specialty care needs for affected infants. The care requirements for such infants necessitate individualized, multidisciplinary care plans.

SUMMARY

Survivors with CDH are at risk of a number of morbidities that may affect development and function. Infants with large defects, those who have received ECMO, or those with a patch repair are at highest risk. These unique patients, especially those at highest risk, require long-term periodic follow-up by a multidisciplinary team of medical, surgical, and developmental specialists to identify and treat morbidities before additional disability results. Preventive pediatric health care according to guidelines developed by the American Academy of Pediatrics is recommended for all children, including those with CDH.⁴⁹⁻⁵² To emphasize the importance of follow-up for specific morbidities associated with CDH, additional suggestions are provided (Table 1). These are most applicable to children with extraordinary medical and surgical complications associated with CDH and should be individualized depending on the specific needs of each infant.

SECTION ON SURGERY, 2006-2007

Kurt D. Newman, MD, Chairperson
Mary Lynn Brandt, MD
Richard R. Ricketts, MD
Robert C. Schamberger, MD
Brad W. Warner, MD
*Kevin P. Lally, MD

STAFF

Aleksandra Stolic, MPH

COMMITTEE ON FETUS AND NEWBORN, 2006-2007

Ann R. Stark, MD, Chairperson
David H. Adamkin, MD
Daniel G. Batton, MD

Edward F. Bell, MD
Vinod K. Bhutani, MD
Susan E. Denson, MD
Gilbert I. Martin, MD
Kristi L. Watterberg, MD
*William Engle, MD

LIAISONS

Keith J. Barrington, MD
Canadian Paediatric Society
Gary D. V. Hankins, MD
American College of Obstetrics and Gynecology
Tonse N. K. Raju, MD
National Institutes of Health
Kay M. Tomashek, MD
Centers for Disease Control and Prevention
Carol Wallman, MSN
National Association of Neonatal Nurses and
Association of Women's Health, Obstetric and
Neonatal Nurses

STAFF

Jim Couto, MA

*Lead authors

REFERENCES

1. Muratore CS, Wilson JM. Congenital diaphragmatic hernia: where are we and where do we go from here? *Semin Perinatol.* 2000;24(6):418-428
2. Ssemakula N, Stewart DL, Goldsmith LJ, Cook LN, Bond SJ. Survival of patients with congenital diaphragmatic hernia during the ECMO era: an 11-year experience. *J Pediatr Surg.* 1997;32(12):1683-1689
3. Wilson JM, Lund DP, Lillehei CW, Vacanti JP. Congenital diaphragmatic hernia: a tale of two cities—the Boston experience. *J Pediatr Surg.* 1997;32(3):401-405
4. Lally KP, Lally PA, Van Meurs KP, et al. Treatment evolution in high-risk congenital diaphragmatic hernia: ten years' experience with diaphragmatic agenesis. *Ann Surg.* 2006;244(4):505-513
5. Davis PJ, Firmin RK, Manktelow B, et al. Long-term outcome following extracorporeal membrane oxygenation for congenital diaphragmatic hernia: the UK experience. *J Pediatr.* 2004;144(3):309-315
6. Van Meurs KP, Robbins ST, Reed VL, et al. Congenital diaphragmatic hernia: long-term outcome in neonates treated with extracorporeal membrane oxygenation. *J Pediatr.* 1993;122(6):893-899
7. Ijsselstijn H, Tibboel D, Hop WJ, Molenaar JC, de Jongste JC. Long-term pulmonary sequelae in children with congenital diaphragmatic hernia. *Am J Respir Crit Care Med.* 1997;155(1):174-180
8. Muratore CS, Kharasch V, Lund DP, et al. Pulmonary morbidity in 100 survivors of congenital diaphragmatic hernia monitored in a multidisciplinary clinic. *J Pediatr Surg.* 2001;36(1):133-140
9. Jaillard SM, Pierrat V, Dubois A, et al. Outcome at 2 years of infants with congenital diaphragmatic hernia: a population-based study. *Ann Thorac Surg.* 2003;75(1):250-256
10. Bagolan P, Casaccia G, Crescenzi F, Nahom A, Trucchi A, Giorlandino C. Impact of a current treatment protocol on outcome of high-risk congenital diaphragmatic hernia. *J Pediatr Surg.* 2004;39(3):313-318

11. Wischermann A, Holschneider AM, Hubner U. Long-term follow-up of children with diaphragmatic hernia. *Eur J Pediatr Surg.* 1995;5(1):13–18
12. Dillon PW, Cilley R, Mauger D, Zachary C, Meier A. The relationship between pulmonary artery pressures and survival in congenital diaphragmatic hernia. *J Pediatr Surg.* 2004;39(3):307–312
13. Okuyama H, Kubota A, Kawahara H, Oue T, Kitayama Y, Yagi M. Correlation between lung scintigraphy and long-term outcome in survivors of congenital diaphragmatic hernia. *Pediatr Pulmonol.* 2006;41(9):882–886
14. Arena F, Baldari S, Centorrino A, et al. Mid- and long-term effects on pulmonary perfusion, anatomy and diaphragmatic motility in survivors of congenital diaphragmatic hernia [published correction appears in *Pediatr Surg Int.* 2006;22(3):304]. *Pediatr Surg Int.* 2005;21(12):954–959
15. Falconer AR, Brown RA, Helms P, Gordon I, Baron JA. Pulmonary sequelae in survivors of congenital diaphragmatic hernia. *Thorax.* 1990;45(2):126–119
16. Vanamo K, Rintala R, Sovijärvi A, et al. Long-term pulmonary sequelae in survivors of congenital diaphragmatic defects. *J Pediatr Surg.* 1996;31(8):1096–1100
17. Bos AP, Hussain SM, Hazebroek FW, Tibboel D, Meradji M, Molenaar JC. Radiographic evidence of bronchopulmonary dysplasia in chronic lung disease survivors. *Pediatr Pulmonol.* 1993;15(4):231–234
18. Meissner HC, Long SS; American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections [technical report]. *Pediatrics.* 2003;112(6 pt 1):1447–1452
19. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections [policy statement]. *Pediatrics.* 2003;112(6 pt 1):1442–1446
20. Muratore CS, Utter S, Jaksic T, Lund DP, Wilson JM. Nutritional morbidity in survivors of congenital diaphragmatic hernia. *J Pediatr Surg.* 2001;36(8):1171–1176
21. Stolar CJ, Levy JP, Dillon PW, Reyes C, Belamarich P, Berdon WE. Anatomic and functional abnormalities of the esophagus in infants surviving congenital diaphragmatic hernia. *Am J Surg.* 1990;159(2):204–207
22. Fasching G, Huber A, Uray E, Sorantin E, Lindbichler F, Mayr J. Gastroesophageal reflux and diaphragmatic motility after repair of congenital diaphragmatic hernia. *Eur J Pediatr Surg.* 2000;10(6):360–364
23. Koot VCM, Bergmeijer JH, Bos AP, Molenaar JC. Incidence and management of gastroesophageal reflux after repair of congenital diaphragmatic hernia. *J Pediatr Surg.* 1993;28(1):48–52
24. Kieffer J, Sapin E, Berg A, Beaudoin S, Bary F, Helardot PG. Gastroesophageal reflux after repair of congenital diaphragmatic hernia. *J Pediatr Surg.* 1995;30(9):1330–1333
25. Sigalet DL, Nguyen LT, Aldolph V, Laberge JM, Hong AR, Guttman FM. Gastroesophageal reflux associated with large diaphragmatic hernias. *J Pediatr Surg.* 1994;29(9):1262–1265
26. Vanamo K, Rintala RJ, Lindahl H, Louhimo I. Long-term gastrointestinal morbidity in patients with congenital diaphragmatic defects. *J Pediatr Surg.* 1996;31(4):551–554
27. Nobuhara KK, Lund DP, Mitchell J, Karasch V, Wilson JM. Long-term outlook for survivors of congenital diaphragmatic hernia. *Clin Perinatol.* 1996;23(4):873–887
28. Lund DP, Mitchell J, Karasch V, Quigley S, Kuehn M, Wilson JM. Congenital diaphragmatic hernia: the hidden morbidity. *J Pediatr Surg.* 1994;29(2):258–264
29. Bouman NH, Koot HM, Tibboel D, Hazebroek FW. Children with congenital diaphragmatic hernia are at risk for lower levels of cognitive functioning and increased emotional and behavioral problems. *Eur J Pediatr Surg.* 2000;10(1):3–7
30. McGahren ED, Mallik K, Rodgers BM. Neurological outcome is diminished in survivors of congenital diaphragmatic hernia requiring extracorporeal membrane oxygenation. *J Pediatr Surg.* 1997;32(8):1216–1220
31. Hunt RW, Kean MJ, Stewart MJ, Inder TE. Patterns of cerebral injury in a series of infants with congenital diaphragmatic hernia utilizing magnetic resonance imaging. *J Pediatr Surg.* 2004;39(1):31–36
32. Davenport M, Rivlin E, D'Souza SW, Bianchi A. Delayed surgery for congenital diaphragmatic hernia: neurodevelopmental outcome in late childhood. *Arch Dis Child.* 1992;67(11):1353–1356
33. Rasheed A, Tindall S, Cueny DL, Klein MD, Delaney-Black V. Neurodevelopmental outcome after congenital diaphragmatic hernia: extracorporeal membrane oxygenation before and after surgery. *J Pediatr Surg.* 2001;36(4):539–544
34. Stolar CJ, Crisafi MA, Driscoll YT. Neurocognitive outcome for neonates treated with extracorporeal membrane oxygenation: are infants with congenital diaphragmatic hernia different? *J Pediatr Surg.* 1995;30(2):366–371; discussion 371–372
35. Cortes RA, Keller RL, Townsend T, et al. Survival of severe congenital diaphragmatic hernia has morbid consequences. *J Pediatr Surg.* 2005;40(1):36–45; discussion 45–46
36. Crankson SJ, Al Jadaan SA, Namshan MA, Al-Rabeeh AA, Oda O. The immediate and long-term outcomes of newborns with congenital diaphragmatic hernia. *Pediatr Surg Int.* 2006;22(4):335–340
37. Bernbaum J, Schwartz IP, Gerdes M, D'Agostino JA, Coburn CE, Polin RA. Survivors of extracorporeal membrane oxygenation at 1 year of age: the relationship of primary diagnosis with health and neurodevelopmental sequelae. *Pediatrics.* 1995;96(5 pt 1):907–913
38. Cheung PY, Tyebkhan JM, Peliowski A, Ainsworth W, Robertson CM. Prolonged use of pancuronium bromide and sensorineural hearing loss in childhood survivors of congenital diaphragmatic hernia. *J Pediatr.* 1999;135(2 pt 1):233–239
39. Robertson CM, Tyebkhan JM, Hagler ME, Cheung PY, Peliowski A, Etches PC. Late-onset, progressive sensorineural hearing loss after severe neonatal respiratory failure. *Otol Neurotol.* 2002;23(3):353–356
40. Masi R, Capolupo I, Casaccia G, et al. Sensorineural hearing loss is frequent and progressive in infants with high risk congenital diaphragmatic hernia not treated with extracorporeal membrane oxygenation [abstr]. Presented at the 53rd annual congress of the British Association of Paediatric Surgeons; July 18–21, 2006; Stockholm, Sweden. Abstract 072
41. Fligor BJ, Neault MW, Mullen CH, Feldman HA, Jones DT. Factors associated with sensorineural hearing loss among survivors of extracorporeal membrane oxygenation therapy. *Pediatrics.* 2005;115(6):1519–1528
42. Lally KP, Paranka MS, Roden J, et al. Congenital diaphragmatic hernia: stabilization and repair on ECMO. *Ann Surg.* 1992;216(5):569–573
43. Moss RL, Chen CM, Harrison MR. Prosthetic patch durability in congenital diaphragmatic hernia: a long-term follow-up study. *J Pediatr Surg.* 2001;36(1):152–154
44. Vanamo K, Peltonen J, Rintala R, Lindahl H, Jaaskelainen J, Louhimo I. Chest wall and spinal deformities in adults with congenital diaphragmatic defects. *J Pediatr Surg.* 1996;31(6):851–854
45. Cohen MS, Rychik J, Bush DM, et al. Influence of congenital

- heart disease on survival in children with congenital diaphragmatic hernia. *J Pediatr*. 2002;141(1):25–30
46. Fauza DO, Wilson JM. Congenital diaphragmatic hernia and associated anomalies: their incidence, identification, and impact on prognosis. *J Pediatr Surg*. 1994;29(8):1113–1117
47. Hartman GE. Diaphragmatic hernia. In: Behrman RE, Kliegman RM, Jenson HB, eds. *Nelson Textbook of Pediatrics*. 17th ed. Philadelphia, PA: WB Saunders; 2004:1353–1355
48. Graziano JN; Congenital Diaphragmatic Hernia Study Group. Cardiac anomalies in patients with congenital diaphragmatic hernia and their prognosis: a report from the Congenital Diaphragmatic Hernia Study Group. *J Pediatr Surg*. 2005;40(6):1045–1049
49. American Academy of Pediatrics. *Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents*. 3rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2007
50. American Academy of Pediatrics, Committee on Practice and Ambulatory Medicine. Recommendations for preventive pediatric health care. *Pediatrics*. 2000;105(3):645–646
51. Follow-up care of high-risk infants. *Pediatrics*. 2004;114(5 suppl):1377–1397
52. Joint Committee on Infant Hearing. Year 2000 position statement: principles and guidelines for early hearing detection and intervention programs. *Pediatrics*. 2000;106(4):798–817

Postdischarge Follow-up of Infants With Congenital Diaphragmatic Hernia
Section on Surgery and the Committee on Fetus and Newborn
Pediatrics 2008;121;627-632
DOI: 10.1542/peds.2007-3282

Updated Information & Services	including high-resolution figures, can be found at: http://www.pediatrics.org/cgi/content/full/121/3/627
References	This article cites 49 articles, 11 of which you can access for free at: http://www.pediatrics.org/cgi/content/full/121/3/627#BIBL
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Surgery http://www.pediatrics.org/cgi/collection/surgery
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.pediatrics.org/misc/Permissions.shtml
Reprints	Information about ordering reprints can be found online: http://www.pediatrics.org/misc/reprints.shtml

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

